IRCT20190804044429N6RecruitingPhase 2
Efficacy and safety of nasal spray of mometasone 0.05%on olfactory improvement in patients with COVID-19: A randomized, double blind clinical trial
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •Inclusion criteria are adults over the age of 18 with a diagnosis of COVID-19 based on clinical criteria (presence of any symptoms of cough, shortness of breath, fever, and CT scan of the lung for evidence of involvement consistent with COVID-19 infection) or PCR and
- •had an olfactory dysfunction ( reduced or loss of sense of smell) for two weeks
Exclusion Criteria
- •Pregnancy and lactation
- •History of olfactory dysfunction
- •Taking drugs that affect the olfactory disorders
- •Corticosteroids chronic use
- •Nasal anatomic dysfunction
- •Existence of dry ducts or nasal bleeding
- •Existence of herpetic lesion
- •Dissatisfaction with participating in the study
Investigators
Similar Trials
Completed
Phase 3
Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)Rhinitis, AllergicNCT03855228Organon and Co704
Completed
Phase 3
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)Perennial Allergic RhinitisNCT00783224Organon and Co351
Active, not recruiting
Phase 1
An exploratory study of mometasone furoate nasal spray in patients with moderate-severe persistent allergic rhinitis and intermittent asthma: effects on the quality of life evaluated with the Rhinasthma questionnaire - NDpersistent allergic rhinitis and concomitant intermittent asthmaMedDRA version: 9.1 Level: LLT Classification code 10039085 Term: Rhinitis allergicEUCTR2007-004683-45-ITSCHERING-PLOUGH56
Completed
Phase 4
The effect of topical steroid nasal spray, Mometasone Furoate Hydrate, on the slpeep sleep quality of pateints with perennial allergic rhinitisperennial allergic rhinitisJPRN-UMIN000003233Faculty of medicine, University of Fukui45
Completed
Phase 3
A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)Seasonal Allergic RhinitisNCT01673659Padagis LLC1,220